Navigation Links
Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
Date:6/1/2011

ANAHEIM, Calif., June 1, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at The Jefferies Global Healthcare Conference to be held June 6-9, 2011 at the Grand Hyatt in New York City.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Thursday, June 9, 2011 at 10:30 a.m. ET.

To listen to the audio web cast of the presentation during or after the event, please visit: www.questcor.com.  The replay will be available for ninety days after the event.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
2. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
3. Lexicon Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
4. Amylin Pharmaceuticals to Present at Goldman Sachs 32nd Annual Global Healthcare Conference and Jefferies Global Life Sciences Conference
5. Avanir Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
6. MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
7. Watson Acquires Specifar Pharmaceuticals
8. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
9. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
10. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
11. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... On Thursday, February 11, 2-1-1 San ... health and disaster services, and the Community Information ... care coordination and service delivery for the community to ... to better connect service providers to the information they ... Diego has handled more than 2.5 million ...
(Date:2/5/2016)... -- Australian-US drug discovery and development company, Novogen Limited (ASX:NRT; ... new Chairman, Mr John O,Connor , and new Deputy ... James Garner , has also been formally appointed to ... Mr Iain Ross , will resume his role on ... Garner , has also been formally appointed to the Board ...
(Date:2/4/2016)... February 4, 2016 - New FDA action date of ... New FDA action date of July 22, 2016 ... July 22, 2016   - Lifitegrast ... past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in the past ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific Instruments ... host live demos and poster sessions, and present on the analysis of mycotoxins ... place March 6 to 10 at the Georgia World Congress Center in Atlanta, ...
Breaking Biology Technology:
(Date:1/25/2016)... 2016   Unisys Corporation (NYSE: UIS ) today ... (JFK) International Airport, New York City , to ... attempting to enter the United States using ... pilot testing of the system at Dulles last year. ... JFK during January 2016. --> pilot testing of ...
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/p74whf/global_biometrics ... "Global Biometrics Market in Retail Sector ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ... Market in Retail Sector 2016-2020" report ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):